MCID: MLG079
MIFTS: 38

Malignant Pleural Mesothelioma malady

Cancer diseases category

Aliases & Classifications for Malignant Pleural Mesothelioma

About this section

Aliases & Descriptions for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma 8 10 61
Malignant Mesothelioma of Pleura 8
 
Pleural Malignant Mesothelioma 44


Classifications:



External Ids:

Disease Ontology8 DOID:7474
NCIt39 C7376

Summaries for Malignant Pleural Mesothelioma

About this section
Disease Ontology:8 A pleural cancer that has material basis in mesothelium cells.

MalaCards based summary: Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to lung cancer and breast cancer. An important gene associated with Malignant Pleural Mesothelioma is MIR34B (microRNA 34b), and among its related pathways are miRNAs involved in DDR and 2 Naphthylamine and 2 Nitronaphtalene metabolism. The compounds vitamin e and S-(PGJ2)-glutathione have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and endothelial.

Related Diseases for Malignant Pleural Mesothelioma

About this section

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:



Diseases related to malignant pleural mesothelioma

Symptoms for Malignant Pleural Mesothelioma

About this section

Drugs & Therapeutics for Malignant Pleural Mesothelioma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Alimta13 38 PEMETREXED (also Pemetrexed Disodium) Eli Lilly Approved February 2004
FDA Label: Alimta
Malady that Drug Treats: Mesothelioma
Indications and Usage:13 ALIMTA┬«; is a folate analog metabolic inhibitor indicated for:; Locally Advanced or Metastatic Nonsquamous Non-Small Cell; Lung Cancer:; Initial treatment in combination with cisplatin. (1.1); Maintenance treatment of patients whose disease has not; progressed after four cycles of platinum-based first-line; chemotherapy. (1.2); After prior chemotherapy as a single-agent. (1.3); Mesothelioma: in combination with cisplatin. (1.4); Limitations of Use:; ALIMTA is not indicated for the treatment of patients with; squamous cell non-small cell lung cancer. (1.5)
DrugBank Targets:11 1. Thymidylate synthase; 2. Bifunctional purine biosynthesis protein PURH; 3. Dihydrofolate reductase; 4. Trifunctional purine biosynthetic protein adenosine-3
Mechanism of Action:13 
Target: folic acid/ thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase
Action: antagonist/ inhibitor
FDA: ALIMTA, pemetrexed for injection, is a folate analog metabolic inhibitor that exerts its action by disrupting folatedependent; metabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibits; thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT),; which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.; Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate binding; protein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzyme; folylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.; Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to a; lesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-life; resulting in prolonged drug action in malignant cells.

Drug clinical trials:

Search ClinicalTrials for Malignant Pleural Mesothelioma

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Genetic Tests for Malignant Pleural Mesothelioma

About this section

Anatomical Context for Malignant Pleural Mesothelioma

About this section

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

31
Lung, Testes, Endothelial, T cells, Lymph node, Bone, Brain, Breast, Spinal cord, Placenta, Tongue

Animal Models for Malignant Pleural Mesothelioma or affiliated genes

About this section

Publications for Malignant Pleural Mesothelioma

About this section

Articles related to Malignant Pleural Mesothelioma:

(show top 50)    (show all 655)
idTitleAuthorsYear
1
Malignant pleural mesothelioma presenting as a spontaneous pneumothorax. (25802741)
2015
2
Loss of mir-223 and JNK Signalling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma. (25824152)
2015
3
BAP1 Protein is a Progression Factor in Malignant Pleural Mesothelioma. (23963927)
2014
4
Combination effect of photodynamic therapy using NPe6 with pemetrexed for human malignant pleural mesothelioma cells. (25385189)
2014
5
Does miR-1 Play a Role in Malignant Pleural Mesothelioma Development and Progression? (24297134)
2013
6
Patterns of disease progression on 18F-fluorodeoxyglucose positron emission tomography-computed tomography in patients with malignant pleural mesothelioma undergoing multimodality therapy with pleurectomy/decortication. (23963351)
2013
7
Is galectin-3 antibody a useful marker in the diagnosis of malignant pleural mesothelioma? (23537297)
2013
8
Antitumor effect and antiangiogenic potential of the mTOR inhibitor temsirolimus against malignant pleural mesothelioma. (24378576)
2013
9
Malignant Pleural Mesothelioma Presenting as Acute Empyema with Severe Leukocytosis. (24088916)
2013
10
ERCC1, MLH1, MSH2, MSH6, and I^III-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma. (23810210)
2013
11
Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma. (23690193)
2013
12
Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Diseases Board in New South Wales, Australia. (22909129)
2013
13
Radiotherapy for the treatment of pain in malignant pleural mesothelioma: A systematic review. (24314815)
2013
14
A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma. (22895142)
2012
15
Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. (21937141)
2012
16
FDG PET/CT Response Evaluation in Malignant Pleural Mesothelioma Patients Treated with Talc Pleurodesis and Chemotherapy. (22670158)
2012
17
A biomarker profile for predicting efficacy of cisplatin-vinorelbine therapy in malignant pleural mesothelioma. (22960937)
2012
18
Photodynamic therapy for malignant pleural mesothelioma. (23055222)
2012
19
Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma. (22734486)
2012
20
Malignant pleural mesothelioma: factors influencing the prognosis. (23413596)
2012
21
Multicentric study on malignant pleural mesothelioma in Turkey: clinicopathologic and survival characteristics of 282 patients. (22722923)
2012
22
Data-driven information retrieval in heterogeneous collections of transcriptomics data links SIM2s to malignant pleural mesothelioma. (22106335)
2012
23
SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model. (22574723)
2012
24
High prevalence of serum antibodies reacting with simian virus 40 capsid protein mimotopes in patients affected by malignant pleural mesothelioma. (23071320)
2012
25
Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. (22412141)
2012
26
Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. (21310625)
2011
27
Lack of evidence in malignant pleural mesothelioma surgery. (21345821)
2011
28
Extrapleural pneumonectomy in malignant pleural mesothelioma. (21914759)
2011
29
The evolution of multimodality therapy for malignant pleural mesothelioma. (21404104)
2011
30
Advances in the biology of malignant pleural mesothelioma. (21288646)
2011
31
Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. (20878622)
2010
32
High-dose-rate surface brachytherapy to boost elongated, curvilinear incisional scars after extrapleural pneumonectomy for malignant pleural mesothelioma treated with adjuvant intensity-modulated radiation therapy. (19846346)
2010
33
Translational therapies for malignant pleural mesothelioma. (20406091)
2010
34
Multimodality treatment of malignant pleural mesothelioma with or without immunotherapy: does it change anything? (20053697)
2010
35
Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy? (21114772)
2010
36
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. (20525721)
2010
37
A rare cause of dysphagia: malignant pleural mesothelioma in the posterior mediastinum. (20868849)
2010
38
Retreatment of recurrent malignant pleural mesothelioma with cisplatin and pemetrexed. (20224880)
2010
39
Placenta growth factor expression has prognostic value in malignant pleural mesothelioma. (19632388)
2009
40
Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. (19233506)
2009
41
Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma. (19351750)
2009
42
Survival and relapse pattern after trimodality therapy for malignant pleural mesothelioma. (19908112)
2009
43
Tract metastasis from previously unknown malignant pleural mesothelioma: a case report. (19830019)
2009
44
Unusual features of malignant pleural mesothelioma metastatic to the mediastinal lymph nodes. (18301236)
2008
45
Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-alpha in malignant pleural mesothelioma. (17253597)
2007
46
Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma. (17080237)
2007
47
Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007 - an update]. (18235409)
2007
48
A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses. (17671130)
2007
49
Squamous cell carcinoma of the lung producing granulocyte colony-stimulating factor and resembling a malignant pleural mesothelioma. (15005252)
2004
50
Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma. (8897701)
1996

Variations for Malignant Pleural Mesothelioma

About this section

Expression for genes affiliated with Malignant Pleural Mesothelioma

About this section
Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Pathways for genes affiliated with Malignant Pleural Mesothelioma

About this section

Pathways related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.9MIR34B, MIR92A1
29.7GSTA4, GSTA2
39.6MIR34B, MIR92A1, MIR625
4
Show member pathways
glutathione-mediated detoxification I36
glutathione redox reactions I36
glutathione redox reactions II36
4-hydroxy-2-nonenal detoxification36
Glutathione metabolism59
Glutathione metabolism36
9.1GSTA4, GSTT2, GSTA2, GSTM3
5
Show member pathways
9.1GSTM3, GSTA2, GSTT2, GSTA4
6
Show member pathways
9.1GSTM3, GSTA2, GSTT2, GSTA4

Compounds for genes affiliated with Malignant Pleural Mesothelioma

About this section
Sources:
50PharmGKB, 11DrugBank, 24HMDB, 44Novoseek
See all sources

Compounds related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

(show all 14)
idCompoundScoreTop Affiliating Genes
1vitamin e50 1110.6GSTA2, GSTM3
2S-(PGJ2)-glutathione249.4GSTM3, GSTA4, GSTT2, GSTA2
34-Hydroxyestrone-2-S-glutathione249.4GSTM3, GSTA2, GSTT2, GSTA4
4Estrone-2,3-quinone249.4GSTA4, GSTT2, GSTA2, GSTM3
5Estrone-3,4-quinone249.4GSTA4, GSTT2, GSTA2, GSTM3
6noradrenochrome44 2410.4GSTA4, GSTT2, GSTA2, GSTM3
72-Hydroxyestrone-1-S-glutathione249.4GSTA4, GSTT2, GSTA2, GSTM3
82-Hydroxyestrone-4-S-glutathione249.3GSTA4, GSTT2, GSTA2, GSTM3
9hydrochloric acid44 2410.3GSTM3, GSTA2, GSTT2, GSTA4
10adrenochrome44 2410.3GSTM3, GSTA2, GSTT2, GSTA4
11gsts449.2GSTA4, GSTT2, GSTA2, GSTM3
12Glutathione24 1110.2GSTM3, GSTA2, GSTT2, GSTA4
13Water249.1GSTA4, GSTT2, GSTA2, GSTM3
14sulfate44 2410.0GSTM3, GSTA2, GSTT2, GSTA4

GO Terms for genes affiliated with Malignant Pleural Mesothelioma

About this section

Biological processes related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1xenobiotic metabolic processGO:00068059.4GSTA4, GSTA2, GSTM3
2glutathione derivative biosynthetic processGO:019016879.3GSTA4, GSTA2, GSTM3
3glutathione metabolic processGO:00067499.1GSTA4, GSTA2, GSTM3

Molecular functions related to Malignant Pleural Mesothelioma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1glutathione transferase activityGO:00043649.1GSTA4, GSTT2, GSTA2, GSTM3

Sources for Malignant Pleural Mesothelioma

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet